Early insight into antibody-dependent enhancement after SARS-CoV-2 mRNA vaccination
Human vaccines & immunotherapeutics, 2021•Taylor & Francis
Current vaccines, which induce a B-cell-mediated antibody response against the spike
protein of SARS-CoV-2, have markedly reduced infection rates. However, the emergence of
new variants as a result of SARS-CoV-2 evolution requires the development of novel
vaccines that are T-cell-based and that target mutant-specific spike proteins along with
ORF1ab or nucleocapsid protein. This approach is more accommodative in inducing highly
neutralizing antibodies, without the risk of antibody-dependent enhancement, as well as …
protein of SARS-CoV-2, have markedly reduced infection rates. However, the emergence of
new variants as a result of SARS-CoV-2 evolution requires the development of novel
vaccines that are T-cell-based and that target mutant-specific spike proteins along with
ORF1ab or nucleocapsid protein. This approach is more accommodative in inducing highly
neutralizing antibodies, without the risk of antibody-dependent enhancement, as well as …
Abstract
Current vaccines, which induce a B-cell-mediated antibody response against the spike protein of SARS-CoV-2, have markedly reduced infection rates. However, the emergence of new variants as a result of SARS-CoV-2 evolution requires the development of novel vaccines that are T-cell-based and that target mutant-specific spike proteins along with ORF1ab or nucleocapsid protein. This approach is more accommodative in inducing highly neutralizing antibodies, without the risk of antibody-dependent enhancement, as well as memory CD8+T-cell immunity.
Taylor & Francis Online以上显示的是最相近的搜索结果。 查看全部搜索结果